Anca Milea

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies”.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3706

N/A

4.4DataRank · unranked

198 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampulla—Site of Origin of Serous Carcinoma of the Ovary

Cancers(2020)10.3390/cancers12051090

N/A

0DataRank · unranked

27 citations

Omar L. Nelson, Leah V. Dodds, Victoria DeCastro, Iru Paudel, Anca Milea +8 more

Hormone Receptor Expression and Disease Prognosis in High-Grade Serous Ovarian Cancer

medRxiv(2023)10.1101/2023.04.21.23288934

N/A

0DataRank · unranked

1 citations

Alex P. Sanchez‐Covarrubias, Ramlogan Sowamber, Anca Milea, André Pinto, Yuguang Ban +4 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017.v1

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more